JWCAR201 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR201 in patients with B cell driven hematology malignancy and autoimmune diseases

开始日期2024-09-01

申办/合作机构

上海交通大学医学院附属仁济医院

[+1]

NCT06517004 / Recruiting临床1期IIT

An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

This is an open-label, single-arm study to investigate the efficacy and safety signals of JWCAR201 amongst subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

开始日期2024-07-18

申办/合作机构

复旦大学

100 项与 JWCAR201 相关的临床结果

登录后查看更多信息

100 项与 JWCAR201 相关的转化医学

登录后查看更多信息

100 项与 JWCAR201 相关的专利（医药）

登录后查看更多信息

项与 JWCAR201 相关的文献（医药）

Blood Cancer Journal

Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial

Article

作者: Yu, Chuan ; Wang, Lijun ; Chen, Ziren ; Xu, Yuanyuan ; Tan, Kun ; Qiao, Jingqiao ; Li, Yisheng ; Zhao, Weiqiang ; Kang, Qingzheng ; Wang, Lei ; Xu, Yang ; Wang, Shuhong ; Wang, Lixin ; Fang, Chuling ; Yu, Li ; Huang, Wenfa ; Guo, Xiao ; Tang, Zhixiong ; Wang, Yiran

Non-Hodgkin lymphoma (NHL) is a common malignancy in the hematologic system, and traditional therapy has limited efficacy for people with recurrent/refractory NHL (R/R NHL), especially for patients with diffuse large B cell lymphoma (DLBCL). Chimeric antigen receptor (CAR) T-cell therapy is a novel and effective immunotherapy strategy for R/R hematopoietic malignancies, but relapses can occur due to the loss of CAR-T cells in vivo or the loss of antigen. One strategy to avoid antigen loss after CAR-T cell therapy is to target one more antigen simultaneously. Tandem CAR targeting CD19 and CD22 has demonstrated the reliability of tandem CAR-T cell therapy for R/R B-ALL. This study explores the therapeutic potential of tandem CD19/20 CAR-T in the treatment of R/R B cell NHL. The efficacy and safety of autologous CD19/20 CAR-T cells in eleven R/R B cell NHL adult patients were evaluated in an open-label, single-arm trial. Most patients achieved complete response, exhibiting the efficacy and safety of tandem CD19/20 CAR-T cells. The TCR repertoire diversity of CAR-T cells decreased after infusion. The expanded TCR clones in vivo were mainly derived from TCR clones that had increased expression of genes associated with immune-related signaling pathways from the infusion product (IP). The kinetics of CAR-T cells in vivo were linked to an increase in the expression of genes related to immune response and cytolysis/cytotoxicity.

100 项与 JWCAR201 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
大B细胞淋巴瘤	临床1期	中国	上海明聚生物科技有限公司	2024-09-01
系统性红斑狼疮	临床1期	中国	上海明聚生物科技有限公司	2024-09-01
弥漫性大B细胞淋巴瘤	临床1期	中国	复旦大学	2024-07-18